Cognition Therapeutics Inc. has reported a net loss of $6.7 million for the second quarter ended June 30, 2025, compared to a net loss of $7.0 million for the same period in 2024. The company's cash, cash equivalents, and restricted cash equivalents were approximately $11.6 million as of June 30, 2025. Additionally, Cognition Therapeutics has $41.9 million in total obligated grant funds remaining from the National Institute of Aging. Research and development expenses for the quarter were $11.5 million, a slight decrease from $11.6 million in the comparable period of 2024, primarily due to reduced professional fees. General and administrative expenses also decreased to $2.5 million from $3.1 million in the previous year, driven mainly by reduced stock-based compensation expenses. The company highlighted significant progress in its clinical programs, including a productive end-of-phase 2 meeting with the FDA for its Alzheimer's disease program and the initiation of an expanded access program for people with dementia with Lewy bodies. Cognition also surpassed 50% enrollment in its Phase 2 'START' study of zervimesine for early Alzheimer's disease. These advancements emphasize the potential of zervimesine to slow the progression of age-related degenerative diseases. The company estimates that its current cash resources will fund operations and capital expenditures into the second quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.